Dr. Lu is a Full Professor in University of Macau. He received his Ph.D. degree in Shanghai Institute of Meteria Medica, Chinese Academy of Sciences in 2009. Currently, he is mainly engaged in the discovery and mechanism study of anti-cancer compounds based on tumor microenvironment. He is also interested in studying the new targets and strategies for cancer therapy. Dr. Lu has published more than 200 scientific papers in the SCI journals including J Hematol Oncol, Adv Sci, Acta Pharm Sin B and Pharmacol Ther (Total citations 13000+, H-index 60, Scopus). He is the Director of the Editorial Office and Associate Editor of Chinese Medicine. Dr. Lu was awarded as the 2nd Prize of Natural Science: Macao Science and Technology Awards (twice) and CNPHARS Annual Young Pharmacologists.

Dr. Fiona Healy is currently a Post-Doctoral Research Associate at the University of Liverpool, UK. She completed her Pharmacology BSc (Hons) degree in 2019 at the University of Liverpool, followed by her PhD from the same institution in 2024. Her work aims to understand drug resistant and poor prognostic Acute Myeloid Leukaemia. Fiona’s interest in personalised medicine has shaped her project to focus on subsets of patient cohorts who develop NRAS mutations, and whose clonal evolution of AML leads to a poor prognostic or drug resistant phenotype. She is delighted to present a brief summation of her PhD and Post-Doctoral research today. She continues to pursue these research interests and is keen to meet with others interested in the pharmacology of blood cancers. Outside of the lab, Fiona is heavily involved in teaching Pharmacology Undergraduate and Masters’ students. In the coming months, she will transition to a Lecturer role at the University of Liverpool, in the new school of Pharmacy and Pharmaceutical Sciences. Within this role, Fiona is looking to develop her scholarly and pedagogic research, particularly centred around active learning. She would love to meet people who share similar interests at this conference too!

Dr. Li Ting is a Research Assistant Professor at the University of Macau's Institute of Chinese Medical Sciences (ICMS), appointed in 2023. She holds a Ph.D. from ICMS (2018) and completed five years of postdoctoral research at McGill University's Goodman Cancer Research Institute. Her research focuses on novel amino acid-based strategies and new therapeutic targets for aggressive cancer, utilizing multi-model and multi-omics approaches. Dr. Li has published 36 SCI-indexed papers (e.g., in Genes & Development, Journal of Hematology & Oncology), with over 1,600 citations and an h-index of 23. Dr. Li is a Young Editorial Board Member for Chin Med and a peer reviewer for journals including Acta Pharmacologica Sinica B and Chinese Journal of Natural Medicines.

Dr. Andrea Abate, PharmD, PhD, is a Hospital Pharmacist at the Clinical Trial Center of ASST Spedali Civili di Brescia and a postdoctoral researcher in the Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Italy. He completed a PhD in Precision Medicine at the University of Brescia and undertook international research training as a visiting PhD student at the University Hospital Zurich and the University of Birmingham. Dr. Abate also completed residency training in Clinical Pharmacology and Toxicology. His scientific activity focuses on oncological pharmacology, with particular expertise in adrenocortical carcinoma. He is the author or co-author of 30 peer-reviewed publications and has presented extensively at national and international conferences. Dr. Abate has received multiple awards for excellence in pharmacological research, including international research grants and best oral presentation awards.